Brief: Karolinska Development Says Modus Therapeutics Raises SEK 28.3 Mln
Aug 28 (Reuters) - Karolinska Development AB KDEV.ST: MODUS THERAPEUTICS RAISES SEK 28.3 MILLION WITH 189% SUBSCRIPTION RATE PROCEEDS FROM RIGHTS ISSUE ARE INTENDED TO FINANCE CONTINUED DEVELOPMENT OF DRUG CANDIDATE, SEVUPARIN, FOR TREATMENT OF CHRONIC KIDNEY DISEASE Source text: ID:nGNE1v1kyJ Further company coverage: KDEV.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Kdventures AB
See all newsRefile: BRIEF-Umecrine Cognition Gets Notice Of Allowance In US
Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
Brief: KDventures' AnaCardio Raises €62.5 Million
Brief: Kdventures' Umecrine Cognition Gets Two USPTO Notices Of Allowance For Patent Applications
Brief: Kdventures' Modus Therapeutics Carries Out Directed Issue